Scholarlink

The metabolic syndrome, a group of modifiers such as obesity, diabetes, hypertension, and dyslipidemia, is a major worldwide health issue. Metabolic syndrome is the diagnosis of multiple physiological and biochemical abnormalities, including abdominal obesity, dyslipidemia, raised blood pressure and insulin resistance, atherosclerotic vascular disease, and the presence of other risk factors for cardiovascular disease, such as the metabolic syndrome described above, in a patient with multiple conditions requiring separate treatments, such as obesity, hypertension, type 2 diabetes, atherosclerosis, cardiovascular disease, smoking, and sedentary Incorporation of these systems with nanotechnology impressively improves the delivery of therapeutic agents to target sites with minimal side effects. Liposomes, polymeric nanoparticles, and metal-organic frameworks are incorporated into 3D-printed scaffold to achieve drug targeting, better bioavailability, and stability of the drug. For instance, a hydrogel or scaffold loaded with nanoparticles can be 3D-printed for a targeted delivery system for inflammation, insulin resistance, or vascular complications of metabolic syndrome. Moreover, diagnostic purposes are based on 3D-bioprinted biosensors with different nanomaterial such as graphene or gold nanoparticles to identify biomarkers sensitive and selective. These technologies facilitate proper screening of metabolic syndrome progression, with an occasion to intervene at appropriate time. These fields complement each other to promote a personalized medicine concept that involves tailored clinical actions based on patient’s genetic and metabolic characteristics. Nonetheless, issues such as regulatory issues, capacity issues, and long-term safety of products and their applications are among the outstanding problems of the enormous potential academic discipline. These are challenges that will need intervention in order to actualize this revolutionary technology into practice in the management of metabolic syndrome and positively affect patient outcomes all over the world.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

3D-Printed Nanotechnology-Based Drug Delivery in Diagnosis and Therapeutics of Metabolic Syndrome

  • 章节

  • 发表日期：

    2026年

查看全文
  • Pankaj Kalia,
  • Pooja Thakur,
  • Devinder Kumar,
  • Sunil Dutt,
  • Ashutosh Kumar,
  • Brijesh Kumar,
  • Rajesh Kumar

摘要

The metabolic syndrome, a group of modifiers such as obesity, diabetes, hypertension, and dyslipidemia, is a major worldwide health issue. Metabolic syndrome is the diagnosis of multiple physiological and biochemical abnormalities, including abdominal obesity, dyslipidemia, raised blood pressure and insulin resistance, atherosclerotic vascular disease, and the presence of other risk factors for cardiovascular disease, such as the metabolic syndrome described above, in a patient with multiple conditions requiring separate treatments, such as obesity, hypertension, type 2 diabetes, atherosclerosis, cardiovascular disease, smoking, and sedentary Incorporation of these systems with nanotechnology impressively improves the delivery of therapeutic agents to target sites with minimal side effects. Liposomes, polymeric nanoparticles, and metal-organic frameworks are incorporated into 3D-printed scaffold to achieve drug targeting, better bioavailability, and stability of the drug. For instance, a hydrogel or scaffold loaded with nanoparticles can be 3D-printed for a targeted delivery system for inflammation, insulin resistance, or vascular complications of metabolic syndrome. Moreover, diagnostic purposes are based on 3D-bioprinted biosensors with different nanomaterial such as graphene or gold nanoparticles to identify biomarkers sensitive and selective. These technologies facilitate proper screening of metabolic syndrome progression, with an occasion to intervene at appropriate time. These fields complement each other to promote a personalized medicine concept that involves tailored clinical actions based on patient’s genetic and metabolic characteristics. Nonetheless, issues such as regulatory issues, capacity issues, and long-term safety of products and their applications are among the outstanding problems of the enormous potential academic discipline. These are challenges that will need intervention in order to actualize this revolutionary technology into practice in the management of metabolic syndrome and positively affect patient outcomes all over the world.